{"id":"W2924379719","doi":"10.1093/annonc/mdz046","title":"Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":157,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Daiichi-Sankyo; Prospect Creek Foundation; Agios Pharmaceuticals; Bayer Fund; Bristol-Myers Squibb; FUJIFILM Pharmaceuticals U.S.A.; Genentech; Ovarian Cancer Research Fund; Valeant Pharmaceuticals International; Comprehensive Cancer Center, City of Hope; Takeda Pharmaceuticals U.S.A.; Comprehensive Cancer Center, University of Chicago Medical Center; Memorial Sloan-Kettering Cancer Center; Daiichi Sankyo Europe; Illumina; National Cancer Institute; AbbVie; Novartis; AstraZeneca; National Institutes of Health; Breast Cancer Research Foundation; U.S. Department of Defense; Boehringer Ingelheim; Pfizer","keywords":"KRAS; Concordance; Genotyping; Medicine; Lung cancer; Digital polymerase chain reaction; Liquid biopsy; COLD-PCR; Genotype; ROS1; Cell-free fetal DNA; Cancer research; Oncology; Cancer; Internal medicine; Mutation; Gene; Point mutation; Biology; Adenocarcinoma; Genetics; Polymerase chain reaction; Colorectal cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001254159,0.0002530637,0.0002090766,0.0002657789,0.0001674399,0.0004256337,0.0002488417,0.0005317384,0.0003103462],"category_scores_gemma":[0.001880334,0.000108604,0.0001882052,0.000232452,0.0002123218,0.0001668693,0.0003311855,0.0003645645,0.0001314167],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002991637,"about_ca_system_score_gemma":0.0002630752,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002123636,"about_ca_topic_score_gemma":0.002029421,"domain_scores_codex":[0.99936,0.0001994157,0.00003790864,0.0001881048,0.0001552339,0.00005940003],"domain_scores_gemma":[0.9987853,0.0005547833,0.000140366,0.0001111331,0.0002649354,0.0001434707],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001268425,0.0002037968,0.9038879,0.0000840537,0.00013237,0.000714684,0.0004261479,0.00178273,0.03969092,0.0001532912,0.001134563,0.05052107],"study_design_scores_gemma":[0.0001413729,0.0009890896,0.9711499,0.0000271999,0.0001470017,0.002633062,0.0002631716,0.005372118,0.01596502,0.0002852558,0.00299832,0.0000285612],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.997029,0.0004239923,0.001464628,0.0001168355,0.000004810631,0.00002197083,0.0005029924,0.00002409365,0.0004117467],"genre_scores_gemma":[0.9965237,0.0001467441,0.001885452,0.0001682876,0.000009062454,0.0000212217,0.001104138,0.000005903697,0.0001355956],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002123636,"threshold_uncertainty_score":0.006632686,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02871166766124892,"score_gpt":0.2654595750996026,"score_spread":0.2367479074383536,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}